Immune Checkpoint Inhibitor Toxicity in 2018

JAMA - Journal of the American Medical Association

Volumn 320, Issue 16, 2018, Pages 1702-1703

  Johnson, Douglas B ^a,b   Chandra, Sunandana ^c,d   Sosman, Jeffrey A ^c,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY;

ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MYOCARDITIS; NEOPLASM; PNEUMONIA; SKIN DISEASE; T LYMPHOCYTE; TOXIC HEPATITIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; COLITIS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MYOCARDITIS; NEOPLASMS; PNEUMONIA; SKIN DISEASES; T-LYMPHOCYTES;

EID: 85054515309     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.13995     Document Type: Short Survey

References (9)

1. Schadendorf D, Hodi FS, Robert C, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015; 33 (17): 1889-1894. 25667295
2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018; 378 (2): 158-168. 29320654
3. Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol. 2018;4(1): 98-101. 28817755
4. Weber JS, Hodi FS, Wolchok JD, Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017; 35 (7): 785-792. 28068177
5. Naidoo J, Wang X, Woo KM, Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017; 35 (7): 709-717. 27646942
6. Faje AT, Sullivan R, Lawrence D, Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014; 99 (11): 4078-4085. 25078147
7. Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018; 38 (6): 976-987. 29603856
8. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391 (10124): 933. 29536852
9. Zimmer L, Goldinger SM, Hofmann L, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016; 60: 210-225. 27084345